The Liquid Biopsy Market is experiencing remarkable growth as healthcare systems increasingly adopt minimally invasive diagnostic technologies for cancer detection and disease monitoring. Liquid biopsy enables clinicians to detect cancer-related biomarkers from blood and other body fluids without requiring traditional surgical tissue biopsies. This innovative approach supports earlier...

The Liquid Biopsy Market is positioned at a critical juncture where analytical technology maturation, clinical evidence accumulation, and healthcare delivery transformation are converging to create sustained demand for non-invasive molecular profiling across the cancer care continuum. The practice of oncology has been fundamentally reshaped by precision medicine, with molecular biomarkers now...